Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.
Canadian Physicians and Surgeons Can Now Diagnose MRSA and SA Skin and Soft
Tissue Infections in Less Than One Hour, Leading to More Effective Treatment
SUNNYVALE, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Cepheid
(Nasdaq: CPHD) today announced that Health Canada has issued a medical device
license for its Xpert(TM) MRSA/SA Skin and Soft Tissue (SSTI) test for the
rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA) and
Staphylococcus aureus (SA, typically Methicilli...
Test Simultaneously Identifies and Differentiates More Virulent 027 Strain
from Common Strains
SUNNYVALE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cepheid
(Nasdaq: CPHD) today announced the release of Xpert(TM) C. difficile as a
European CE IVD Mark product under the European Directive on In Vitro
Diagnostic Medical Devices. For the first time, European hospitals will have
access to a reliable, rapid test for Clostridium difficile, which
simultaneously ...
SUNNYVALE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD)
today announced that its executives will be speaking at the following investor
conferences, and invited investors to participate via webcast.
Credit Suisse Global Health Care Conference, Phoenix, AZ
Friday, November 14, 2008 at 8.00 a.m. Mountain Time
Piper Jaffray Health Care Conference, New York, NY
Tuesday, December 2, 2008 at 2.00 p.m. Eastern Time
Accessin...
Fourth 'Moderate Complexity' Categorization Highlights GeneXpert(R) System
Ease-of-Use
SUNNYVALE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD)
today announced the U.S. Food & Drug Administration (FDA) categorized
Cepheid's Xpert(TM) MRSA/SA Blood Culture (BC) test as "Moderate Complexity"
under the Clinical Laboratory Improvement Amendments (CLIA). The new test is
designed for on-demand detection of Methicillin-resistant Staphylococ...
December 2008
?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.